Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Oncology Market: By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel, and Geography
1. Executive Summary |
2. Global Oncology Market Introduction |
2.1. Global Oncology Market - Taxonomy |
2.2. Global Oncology Market -Definitions |
2.2.1. By Drug Class |
2.2.2. By Disease Indications |
2.2.3. By Treatment Options |
2.2.4. By Distribution Channel |
2.2.5. By Region |
3. Global Oncology Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Oncology Market Dynamic Factors - Impact Analysis |
3.6. Impact of COVID 19 on The Market |
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic |
3.8. Mapping Market Players Activities |
3.9. Recent Key Developments |
3.10. Financial Status of the Market Players |
3.11. Recent Acquisitions, Collaborations, and Mergers |
4.Global Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Oncology Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.1. Antimetabolites |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. MAbs |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. XPO1 Inhibitor |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Mitotic Inhibitors |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Multikinase Inhibitors |
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Antineoplastics |
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Oncology Market Forecast, By Disease Indications, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.1. Lung cancer |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Breast cancer |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Prostate cancer |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Cervical cancer |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Colorectal cancer |
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Acute Myeloid Leukemia |
6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Others |
6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7. Market Opportunity Analysis Global Oncology Market Forecast, By Treatment Options, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.1. Surgery |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Chemotherapy |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Immunotherapy |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Targeted Therapy |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Bone marrow transplant |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Bone marrow transplant |
7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
7.7. Hormone therapy |
7.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.7.3. Market Opportunity Analysis |
7.8. Cryoablation |
7.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.8.3. Market Opportunity Analysis |
7.9. Cryoablation |
7.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.9.3. Market Opportunity Analysis |
7.10. Radiofrequency ablation |
7.10.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.10.3. Market Opportunity Analysis |
7.11. Radiation Therapy |
7.11.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.11.1.3. Market Opportunity Analysis |
7.12. Others |
7.12.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.12.3. Market Opportunity Analysis |
8. Market Opportunity Analysis Global Oncology Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
8.1. Hospital Pharmacy |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacy |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacy |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9. Global Oncology Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.1. North America |
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia-Pacific |
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Latin America |
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Middle East and Africa |
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
9.6. Global Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel, and Region, 2023 - 2029 |
10. North America Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
10.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
10.1.1. Antimetabolites |
10.1.2. Antineoplastics |
10.1.3. XPO1 Inhibitor |
10.1.4. Mitotic Inhibitors |
10.1.5. Biomarker testing |
10.1.6. Multikinase Inhibitors |
10.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. Lung cancer |
10.2.2. Breast cancer |
10.2.3. Prostate cancer |
10.2.4. Cervical cancer |
10.2.5. Colorectal cancer |
10.2.6. Acute Myeloid Leukemia |
10.2.7. Others |
10.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Surgery |
10.3.2. Chemotherapy |
10.3.3. Radiation therapy |
10.3.4. Bone marrow transplant |
10.3.5. Immunotherapy |
10.3.6. Hormone therapy |
10.3.7. Targeted drug therapy |
10.3.8. Cryoablation |
10.3.9. Radiofrequency ablation |
10.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Hospital Pharmacy |
10.4.2. Retail Pharmacy |
10.4.3. Online Pharmacy |
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
10.5.1. U.S. |
10.5.2. Canada |
10.6. North America Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
10.7. North America Oncology Market Dynamics - Trends |
11. Europe Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
11.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
11.1.1. Antimetabolites |
11.1.2. Antineoplastics |
11.1.3. XPO1 Inhibitor |
11.1.4. Mitotic Inhibitors |
11.1.5. Biomarker testing |
11.1.6. Multikinase Inhibitors |
11.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. Lung cancer |
11.2.2. Breast cancer |
11.2.3. Prostate cancer |
11.2.4. Cervical cancer |
11.2.5. Colorectal cancer |
11.2.6. Acute Myeloid Leukemia |
11.2.7. Others |
11.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
11.3.1. Surgery |
11.3.2. Chemotherapy |
11.3.3. Radiation therapy |
11.3.4. Bone marrow transplant |
11.3.5. Immunotherapy |
11.3.6. Hormone therapy |
11.3.7. Targeted drug therapy |
11.3.8. Cryoablation |
11.3.9. Radiofrequency ablation |
11.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
11.4.1. Hospital Pharmacy |
11.4.2. Retail Pharmacy |
11.4.3. Online Pharmacy |
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
11.5.1. Germany |
11.5.2. UK |
11.5.3. France |
11.5.4. Italy |
11.5.5. Spain |
11.5.6. Rest of Europe |
11.6. Europe Oncology Market - Opportunity Analysis Index, By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
11.7. Europe Oncology Market Dynamics - Trends |
12. Asia-Pacific Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
12.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
12.1.1. Antimetabolites |
12.1.2. Antineoplastics |
12.1.3. XPO1 Inhibitor |
12.1.4. Mitotic Inhibitors |
12.1.5. Biomarker testing |
12.1.6. Multikinase Inhibitors |
12.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
12.2.1. Lung cancer |
12.2.2. Breast cancer |
12.2.3. Prostate cancer |
12.2.4. Cervical cancer |
12.2.5. Colorectal cancer |
12.2.6. Acute Myeloid Leukemia |
12.2.7. Others |
12.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
12.3.1. Surgery |
12.3.2. Chemotherapy |
12.3.3. Radiation therapy |
12.3.4. Bone marrow transplant |
12.3.5. Immunotherapy |
12.3.6. Hormone therapy |
12.3.7. Targeted drug therapy |
12.3.8. Cryoablation |
12.3.9. Radiofrequency ablation |
12.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Hospital Pharmacy |
12.4.2. Retail Pharmacy |
12.4.3. Online Pharmacy |
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
12.5.1. Japan |
12.5.2. China |
12.5.3. India |
12.5.4. ASEAN |
12.5.5. Rest of Asia-Pacific |
12.6. Asia-Pacific Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
12.7. Asia-Pacific Oncology Market Dynamics - Trends |
13. Latin America Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
13.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
13.1.1. Antimetabolites |
13.1.2. Antineoplastics |
13.1.3. XPO1 Inhibitor |
13.1.4. Mitotic Inhibitors |
13.1.5. Biomarker testing |
13.1.6. Multikinase Inhibitors |
13.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
13.2.1. Lung cancer |
13.2.2. Breast cancer |
13.2.3. Prostate cancer |
13.2.4. Cervical cancer |
13.2.5. Colorectal cancer |
13.2.6. Acute Myeloid Leukemia |
13.2.7. Others |
13.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
13.3.1. Surgery |
13.3.2. Chemotherapy |
13.3.3. Radiation therapy |
13.3.4. Bone marrow transplant |
13.3.5. Immunotherapy |
13.3.6. Hormone therapy |
13.3.7. Targeted drug therapy |
13.3.8. Cryoablation |
13.3.9. Radiofrequency ablation |
13.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Hospital Pharmacy |
13.4.2. Retail Pharmacy |
13.4.3. Online Pharmacy |
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
13.5.1. Brazil |
13.5.2. Argentina |
13.5.3. Rest of Latin America |
13.6. Latin America Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
13.7. Latin America Oncology Market Dynamics - Trends |
14. Middle East and Africa Oncology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, US$ Million) |
14.1. By Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
14.1.1. Antimetabolites |
14.1.2. Antineoplastics |
14.1.3. XPO1 Inhibitor |
14.1.4. Mitotic Inhibitors |
14.1.5. Biomarker testing |
14.1.6. Multikinase Inhibitors |
14.2. By Disease Indications Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
14.2.1. Lung cancer |
14.2.2. Breast cancer |
14.2.3. Prostate cancer |
14.2.4. Cervical cancer |
14.2.5. Colorectal cancer |
14.2.6. Acute Myeloid Leukemia |
14.2.7. Others |
14.3. By Treatment Options Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
14.3.1. Surgery |
14.3.2. Chemotherapy |
14.3.3. Radiation therapy |
14.3.4. Bone marrow transplant |
14.3.5. Immunotherapy |
14.3.6. Hormone therapy |
14.3.7. Targeted drug therapy |
14.3.8. Cryoablation |
14.3.9. Radiofrequency ablation |
14.4. By Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million), Y-o-Y Growth (%) and Market Share (%) |
14.4.1. Hospital Pharmacy |
14.4.2. Retail Pharmacy |
14.4.3. Online Pharmacy |
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (US$ Million) Y-o-Y Growth (%) and Market Share (%) |
14.5.1. Saudi Arabia |
14.5.2. GCC Countries |
14.5.3. South Africa |
14.5.4. Rest of MEA |
14.6. MEA Oncology Market - Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2023 - 2029 |
14.7. MEA Oncology Market Dynamics - Trends |
15. Competition Landscape |
15.1. Strategic Dashboard of Top Market Players |
15.2. Company Profiles (Introduction, Financial Analysis, By Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis) |
15.2.1. ABBVIE INC.AMGEN, INC. |
15.2.2. ASTELLAS PHARMA INC. |
15.2.3. ASTRAZENECA PLC |
15.2.4. BRISTOL-MYERS SQUIBB COMPANY |
15.2.5. F. HOFFMANN-LA ROCHE AG |
15.2.6. JOHNSON & JOHNSON |
15.2.7. MERCK & CO., INC. |
15.2.8. NOVARTIS INTERNATIONAL AG |
15.2.9. PFIZER, INC. |
15.2.10. Celgene Corporation (U.S.) |
16. Research Methodology |
17. Key Assumptions and Acronyms |
Download Free Sample Report
2021 is the base year and 2028 is the forecast year.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
The oncology market key players are: ABBVIE INC., AMGEN, INC., ASTELLAS PHARMA INC., ASTRAZENECA PLC, BRISTOL-MYERS SQUIBB COMPANY, JOHNSON & JOHNSON, MERCK & CO., INC., NOVARTIS INTERNATIONAL AG, PFIZER, INC., Celgene Corporation (U.S.), HOFFMANN-LA ROCHE AG
Key Market Players